Quarterly ResultAug 13, 2026, 04:17 PM
Cadrenal Therapeutics Launches Strategic Partnering Process; Q2 Net Loss $3.3M
AI Summary
Cadrenal Therapeutics reported its second quarter 2026 financial results, including a net loss of $3.3 million and $4.2 million in cash and cash equivalents, expected to fund operations through Q1 2027. Concurrently, the company launched a strategic partnering process for its pipeline assets, CAD-1005, frunexian, and tecarfarin, following positive Phase 2 data for CAD-1005 and a regulatory submission for tecarfarin. The company aims for a capital-efficient model through out-licensing and portfolio monetization.
Key Highlights
- Launched a structured partnering process for CAD-1005, frunexian, and tecarfarin.
- CAD-1005 Phase 2 data showed >25% absolute reduction in thrombotic events.
- Submitted request for Rare Pediatric Disease Designation for tecarfarin on July 8, 2026.
- Private placement generated $3.0M in gross proceeds, with potential for $5.8M more from warrants.
- Q2 2026 net loss was $3.3M, compared to $3.7M in Q2 2025.
- Cash and cash equivalents totaled $4.2M as of early August 2026.
- Cash expected to fund operations through Q1 2027.
- Research and development expenses decreased to $0.7M in Q2 2026 from $1.1M in Q2 2025.
Price Impact
More from CVKD